Knowles Corp (KN) · Oct 22, 2026 · Earnings

Knowles earnings beat as Precision Devices surges

Beat — Revenue $184.0M vs ~$172.1M consensus; non-GAAP EPS $0.38 vs ~$0.36

Knowles’ Q3 earnings beat expectations on strong Precision Devices demand, though MedTech margins narrowed and working-capital use increased.

Knowles is now a focused industrial-technology company built around customized components for MedTech, Defense, Industrial, and Electrification markets, with Precision Devices as the main growth engine. Its portfolio transformation is complete, and the current story is about converting strong orders and design wins into sustained production growth.

The quarter beat the market’s operating bar by a wide margin. Revenue reached $184.0 million, up 20.3% year over year, versus published expectations around $172.1 million; non-GAAP diluted EPS was $0.38 versus consensus around $0.36. That is a genuine earnings beat, not just growth against an easy comparison.

MetricQ3 2026Q3 2025 / expectationRead
Revenue$184.0M$152.9M / ~$172.1M consensusWell above expectations
Non-GAAP diluted EPS$0.38$0.33 / ~$0.36 consensusAbove expectations
Operating cash flow$44.6M$29.1MStrong improvement
Adjusted EBITDA margin26.3%25.8%Slight expansion
Gross margin44.2%45.7%Down 150 bps
Q4 revenue outlook$180M–$190M—Maintained growth trajectory
Q4 non-GAAP EPS outlook$0.39–$0.43—New quarterly guide

Precision Devices is carrying the business. Segment revenue jumped 32.7% to $117.0 million, while adjusted EBITDA margin rose to 27.5% from 25.7%. That supports the company’s claim that defense, industrial, electrification, and MedTech demand is translating into higher factory utilization rather than merely sitting in the order book.

The weaker spot is MedTech and Specialty Audio. Revenue grew only 3.6% to $67.0 million, while adjusted EBITDA margin fell 210 basis points to 41.6%. Management attributes the pressure to inventory reserves and higher R&D and operating spending for longer-term initiatives, so the issue is not demand collapse—but the fastest-growing segment is not converting all incremental revenue into margin yet.

Cash generation improved sharply in the quarter, but working capital deserves attention. Operating cash flow rose to $44.6 million from $29.1 million, yet nine-month adjusted free cash flow fell to $62.4 million from $81.2 million as receivables and inventories absorbed cash. The filing shows inventories at $150.3 million versus $124.6 million at year-end, consistent with the company building capacity and stock ahead of anticipated demand, but it raises the execution burden behind the growth story.

The outlook keeps the bar high without clearly raising it. Q4 revenue is guided to $180 million–$190 million, non-GAAP EPS to $0.39–$0.43, and operating cash flow to $60 million–$70 million. Management also expects full-year 2026 revenue growth of 16% at the midpoint and points to 2027 growth from bookings and new design wins, but the filing does not provide a formal 2027 financial guide.

Bottom line: This is a clear earnings beat driven by a real acceleration in Precision Devices, strengthening Knowles’ industrial-growth story. The main qualification is that MedTech profitability and working-capital intensity remain execution issues beneath the headline result.

What to watch next

Q4 2026 results and 2027 growth targets

Original filing on SEC EDGAR

Knowles earnings beat as Precision Devices surges | KN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.